Filing Flows

Filing Flows › Companies › BioAge Labs › Cash flow

BioAge Labs cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$31.0M in Q3 2026 · −$103M over twelve months

Operating cash flow−$31.0M
Capital spending−$18K
Free cash flow−$31.0M

Analysis

In Q3 2026, BioAge Labs generated −$31.0M of operating cash flow and spent $18K on capital projects, leaving free cash flow of −$31.0M. That is $14.9M less than in Q3 2025 (−$16.1M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$103M; the largest uses were other investing ($218M), operating cash flow ($103M), net borrowing (+) / repaid (−) ($3.5M); besides operations, cash came from other financing ($155M), shares issued ($5.9M); the cash balance fell by $163M.

Operating cash flow was −$31.0M against net income of −$33.5M. The largest differences: stock-based pay +$4.6M, payables −$3.7M, prepaid and other assets −$1.1M.

Free cash flow

BioAge Labs: free cash flow by quarterBioAge Labs: free cash flow by quarter−$5.2MQ4 2024−$17.8MQ1 2025−$20.1MQ2 2025−$16.1MQ3 2025−$28.4MQ4 2025−$24.1MQ1 2026−$19.6MQ2 2026−$31.0MQ3 2026
Operating cash flow less capital spending.
BioAge Labs: operating cash flow against capital spendingBioAge Labs: operating cash flow against capital spendingOperating cash flowCapital spending−$5.1M$26KQ4 2024−$17.4M$426KQ1 2025−$20.0M$159KQ2 2025−$16.0M$22KQ3 2025−$28.3M$112KQ4 2025−$24.0M$26KQ1 2026−$19.3M$328KQ2 2026−$31.0M$18KQ3 2026
Latest (Q3 2026): Operating cash flow −$31.0M, Capital spending $18K.

Capital allocation, year by year

BioAge Labs: where the cash came from (up) and went (down), by fiscal yearBioAge Labs: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2023: Operating cash flow −$37.4MFY2023: Net borrowing $35.0MFY2023: Shares issued $4KFY2023: Capital spending −$166K$35.0MFY2023FY2024: Operating cash flow −$51.5MFY2024: Net borrowing −$6.0MFY2024: Shares issued $634KFY2024: Capital spending −$366K$634KFY2024FY2025: Operating cash flow −$81.6MFY2025: Net borrowing −$6.0MFY2025: Shares issued $17.9MFY2025: Capital spending −$719K$17.9MFY2025
Over these 3 years operating cash flow totalled −$171M; the largest uses were operating cash flow ($171M) and net borrowing ($12.0M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$284M
Debtnone
Net cash$284M
Cash runway2.8 years

BioAge Labs is burning cash: its operations consume cash, a free cash flow of −$103M a year at the current rate against $284M of cash and investments: a runway of about 2.8 years before any new financing.

Where the cash came from and went

BioAge Labs: sources (+) and uses (−) of cash, Q3 2026BioAge Labs: sources (+) and uses (−) of cash, Q3 2026Operating cash flow−$31.0MCash drawn (+) / kept (−)$21.3MOther investing$7.6MShares issued$2.1MExchange rates$35KOther financing$29KCapital spending−$18K
BioAge Labs: sources (+) and uses (−) of cash, TTM to Q3 2026BioAge Labs: sources (+) and uses (−) of cash, TTM to Q3 2026Other investing−$218MCash drawn (+) / kept (−)$163MOther financing$155MOperating cash flow−$103MShares issued$5.9MNet borrowing (+) / repaid (−)−$3.5MCapital spending−$484KExchange rates−$16K

From profit to cash

BioAge Labs: net income to operating cash flow, Q3 2026BioAge Labs: net income to operating cash flow, Q3 2026Net income−$33.5MDepreciation & amortization$100KStock-based pay$4.6MReceivables$60KPayables−$3.7MDeferred revenue$269KPrepaid and other assets−$1.1MOperating cash flow−$31.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$31.0M−$18K—$2.1M$21.3M−$31.0M
Q2 2026−$19.3M−$328K−$500K$1.5M$168M−$19.6M
Q1 2026−$24.0M−$26K−$1.5M$1.7M−$52.9M−$24.1M
Q4 2025−$28.3M−$112K−$1.5M$714K$26.7M−$28.4M
Q3 2025−$16.0M−$22K−$1.5M—$4.8M−$16.1M
Q2 2025−$20.0M−$159K−$1.5M—$37.2M−$20.1M
Q1 2025−$17.4M−$426K−$1.5M—$96.9M−$17.8M
Q4 2024−$5.1M−$26K−$1.5M$27.6M−$19.9M−$5.2M

BioAge Labs: income statement and cash flow

BioAge Labs, Q3 2026: revenue $298K (-86% year over year). The chart follows the revenue to costs, profit and cash.

BioAge Labs: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.